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Abstract
Background: Kidney transplantation (KTx) is the best therapeutic approach for chronic kidney diseases leading to
irreversible kidney failure. Considering the origin of the graft, several studies have reported differences between
living (LD) and deceased donors (DD) in graft and patient survival. These differences seem to be related to multiple
factors including, donor age and time of cold ischemia among others. Many of transplanted organs come from old-
aged DDs, in which pre-transplant biopsy is recommended. However, kidney biopsy has several limitations, and
there is a need to develop alternatives to assess the status of a kidney before transplantation. As the analysis of
urinary extracellular vesicles (uEVs) rendered promising results as non-invasive biomarkers of kidney-related
pathologies, this pilot study aimed to investigate whether profiling uEVs of LDs and DDs may be of help to assess
the quality of the kidney before nephrectomy.
Methods: uEVs from 5 living donors and 7 deceased donors were isolated by size-exclusion chromatography, and
their protein and miRNA content were analysed by liquid chromatography followed by mass spectrometry and
next generation sequencing, respectively. Then, hierarchical clustering and venn diagrams were done with Perseus
software and InteractiVenn tool. Specific EVs data bases were also used for Gene Ontology analysis.
Results: Next generation sequencing revealed that uEVs from DDs contained less miRNAs than LDs, but most of
the DD-expressed miRNAs were shared with LDs (96%). Only miR-326 (targeting the apoptotic-related Bcl2) was
found significantly over-represented in LD. Focusing on the protein content, we detected a low intra-group
correlation in both types of donors. Despite these differences, hierarchical clustering of either miRNA or protein
data could not identify a differential profile between LDs and DDs. Of note, 90% of transplanted patients had a
functional graft after a year from KTx.
Conclusions: In this pilot study we found that, in normo-functional grafts, minor differences in uEVs profile could
not discriminate between LDs and DDs.
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Background
Chronic kidney disease is a public health issue, causing an
important mortality rate and high economic impact [1].
Currently, different replacement therapies for end-stage
renal disease include haemodialysis, peritoneal dialysis
and kidney transplantation (KTx). Of these, only KTx im-
proves the quality of life of the patients, and is clearly bet-
ter compared to dialysis regarding patient survival [2–4].
KTx may be performed using organs from living (LD) or
deceased donors (DD). Although the number of LDs has
increased in the late years [5], the majority of transplanted
organs come from aged DDs in a state of neurological
death. Some of the most important parameters affecting
patient’s survival after transplantation are related to age
(of both donor and recipient), previous pathology of the
recipient and the extent of the ischemia-reperfusion injury
[4, 6–8]. It is widely accepted, and strongly supported, that
transplantation from LDs offers better long-term out-
comes than deceased organ transplants [9–11]; because of
DDs are usually older, have more comorbidities and lon-
ger cold ischemia time than LD [10–12]. Moreover, in
order to maintain the organs in optimal conditions,
hemodynamic stability, adequate oxygenation, the correc-
tion of hypothermia, diabetes insipidus and electrolyte dis-
turbances should be corrected by drug administration
[13]. For these purposes, DDs might receive dopamine,
noradrenalin and vasopressin among other drugs. In
addition, specific antibiotic treatment might be adminis-
tered if infection is suspected [14]. All these maintaining
interventions may modify the quality of the organ.
To date, the quality of the organ before nephrectomy
has only been estimated by sonographic images and kid-
ney biopsy. In fact, kidney biopsy is recommended in ex-
panded criteria donors, including those aged over
60 years, or showing hypertension, diabetes and in
non-beating heart donors [15]. Nevertheless, kidney bi-
opsy requires the invasive sampling of the organ and
thus might affect also its quality. Therefore, alternative
non-invasive techniques are needed to determine the
organ status and predict the KTx outcome.
In this context, Extracellular Vesicles (EVs) have
emerged as a source of non-invasive biomarkers for sev-
eral diseases [16, 17]. In particular, urine EVs (uEVs) are
viewed as a subcellular image of the glomerular and
tubular systems, and changes in their composition may
reflect ongoing events occurring in the renal system
[18–20]. In this sense, a growing number of studies have
proposed several EV-related biomarkers for kidney dys-
function, graft rejection [18, 21–23], or chronic kidney
disease [21, 24, 25]. Also, a recently published study ana-
lysed EVs from graft-preservation fluid to predict de-
layed graft function [26]. However, no reports to date
have investigated the uEVs profiles from LD and DD organs
to distinguish their quality status prior to transplantation.
We aim to profile uEV form living and deceased donors to
define their RNA and protein content before KTx.
In this pilot study, we explored the miRNA and pro-
tein content of uEVs from LD and DD kidney donors.
Using size-exclusion chromatography (SEC) as a minim-
ally altering isolation technique to obtain uEVs [27], we
report the great similarity in the molecular profile of
uEVs from LDs and DDs. Importantly, this correlated
with the kidney function of the transplanted patients,
which showed normal renal function 1 year after trans-
plantation. In addition, we have identified several previ-
ously non-described uEVs miRNAs.
Methods
The study protocols were approved by the Clinical Re-
search Ethics Committee of the Germans Trias i Pujol
University Hospital and conformed to the principles out-
lined in the Declaration of Helsinki. No statistical power
calculation was conducted prior to the study, size sample
was estimated based on previous publications [28–30].
Urine collection
First morning void urine was collected from living kid-
ney donors (n = 5) before undergoing nephrectomy.
Urine samples from deceased kidney donors (n = 7) were
collected directly from the catheter 6 h before surgery
was performed. Immediately after collection, urine (70–
100 mL) was centrifuged at 600 g for 15 min to elimin-
ate cell and debris and frozen at − 80 °C in the presence
of the protease inhibitor AEBSF (0.138 mg/mL; Roche,
Basel, Switzerland).
Urine EV isolation by SEC
Cell-free urine samples were unfrozen overnight at 4 °C
and centrifuged at 17,000 g for 10 min. The supernatant
was kept and the 17,000 g pellet was treated with DTT
(200 mg/mL, Sigma-Aldrich) for 10 min at 37 °C to re-
lease Tamm-Horsfall protein polymers, as previously de-
scribed [31]. The DTT-treated pellet and the 17,000 g
supernatant were mixed and centrifuged again at 17,000 g
for 10 min. Then, supernatant was concentrated by ultra-
filtration, using a 100 kDa cut-off Centricon filter unit
(Millipore, Bedford, MA). One mL of the retained volume
of concentrated urine was then loaded into a 10-mL seph-
arose CL-2B (Sigma) SEC column to isolate uEVs. For
each sample, 20 fractions of 0.5 ml were collected [32].
Nanoparticle tracking analysis
Concentration and size distribution of uEVs were deter-
mined by Nanoparticle Tracking Analysis (NTA) in a
Nanosight LM10–12 (Malvern Instruments Ltd., Mal-
vern, UK) equipped with a 638 nm laser and CCD cam-
era (model F-033). Briefly, samples were diluted 50 to
100 times in PBS to reach optimal concentration for
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instrument linearity. Three videos of 60s time were re-
corded for each sample at 24 °C, at a camera level of 16,
the camera shutter at 30.02 ms and the camera gain set
at 650, as recommended by the manufacturer. Analysis
was performed using the NTA software version 3.0.
Flow cytometry
SEC fractions were incubated with aldehyde/sulfate-latex
beads of 4 μm (Invitrogen, Carlsbad, CA). Then,
EV-coated beads were labelled with anti-CD9 (Clone
VJ1/20), anti-CD63 (Clone TEA 3/18) or polyclonal
mouse IgG isotype (Abcam, Cambrige, UK) and as sec-
ondary antibody FITC-conjugated goat anti-mouse IgG
(Bionova, NS, Canada) was used. Then samples were
analysed by flow cytometry (FacsVerse, BD Biosciences
San Jose, CA). Singlet beads were gated, and the FITC
median fluorescence intensity (MFI) of the EVs-coated
beads was calculated for each fraction using the FlowJo
software (Tree Star, Ashland, OR) [32, 33].
RNA analysis
RNA analyses were performed in samples from 5 LDs
and 5 DDs. Total RNA was extracted from uEVs using
mirCURY kit (Exiqon, Vedbaek, Denmark) following
manufacturer’s instructions with the previous published
modifications [34]. Then, RNA was precipitated using
glycogen (20 mg/mL; Roche); 10% AcNa 3 M, pH 5.2
(Sigma-Aldrich) and 2.5 times (v/v) of absolute ethanol.
RNA profiling was determined using a high resolution
kit (Small RNA kit) in a Bioanalyser 2100 System (Agi-
lent technologies, Santa Clara, CA).
Deep sequencing was performed using TruSeq small
RNA, (Illumina, San Diego, CA). An equimolar pool of
all samples were run on HiSeq2500 (Illumina) using
TruSeq paired end cluster generation (v3 for cBOT).
The DESeq package was used to normalize and analyse
differential expression between the miRNAs found [35].
Qualitative analysis was done based on raw counts and a
given miRNA was accepted as present when the raw
count was of at least 5 copies.
Proteomic analysis
The uEVs-protein content was analysed in DD (n = 5)
and LD (n = 5) by liquid chromatography following mass
spectrometry (LC-MS/MS). Briefly, uEVs proteins were
digested (LysC and trypsin) and injected in an Orbitrap
XL with a 120 min gradient CID method using a 12 cm
column. BSA controls were included both in the diges-
tion and LC-MS/MS analysis for quality control.
The data has been analysed using Proteome Discoverer
(v2.0) an internal version of the search algorithm
Mascot (www.matrixscience.com) against human database
(SwissProt Apr 2015 and UniProt Apr 2015). Peptides
have been filtered based on a 5% False Discovery Rate.
Analysis
Venn diagrams and hierarchical clustering was performed
using the InteractiVenn tool (www.interactivenn.net) [36]
and Perseus software (1.6.0.2) [37, 38]. Further analyses re-
lated to biological function and location were based on spe-
cific databases, for EVs: EVpedia [39, 40], Exocarta [41, 42]
and Vesiclepedia [43]; for miRNAs: mirbase [44]; and for
target prediction: miRDB (mirdb.org/miRDB/) [45].
Results
Clinical and epidemiological characteristics of donors
A total of 5 LD and 7 DD were included in this pilot
study. The LD group included 2 males and 3 females, with
a mean age of 57 years old (ranging from 45 to 69). One
of the LDs was receiving treatment for hypothyroidism
(Levothyroxine) and dyslipemia (statins). Kidney parame-
ters in LDs revealed normal function and no other path-
ologies were detected. Urine samples were collected from
the first morning urine before kidney extraction. After
surgery these donors were further monitored in our hos-
pital for 12 to 26 months, and all of them showed normal
kidney function. Mean time of cold ischemia in the LD
group was of 2.4 h (ranging from 2 to 4 h).
The DD group included 3 males and 4 females, with a
mean age of 67 years old (ranging from 49 to 84). Causes of
death were cerebrovascular accident, trauma, pulmonary
thromboembolism and cardiac event. Most of DDs received
standardized pharmacological treatment to maintain blood
pressure and preserve organ function (detailed in Table 1).
Four of the DDs showed dyslipemia, while serum creatinine
levels of the donors were all between 0.8–3.41 mg/dL (Nor-
mal range 0.7–1.3 mg/dL). Urine samples from DDs were
obtained 6 hours before the surgery. Kidney biopsy was
performed in all of the donors using the Remuzzi scoring
system to assess the histopathology [46]. Grafts showed a
score between 2 and 5, and all were accepted for transplant-
ation. Mean time of cold ischemia in the DD group was
18.5 h (range 13–22 h).
Transplantation details and graft outcome after
transplantation
The study is based on a cohort of 12 donors (5 LD and 7
DD). Two organs from DD were not transplanted due to
thromboembolism (1 organ) and intra-operatory decision of
the surgeon (1 organ), thus a total of 17 kidney transplants
(5LD+ 12DD) were performed (summarized in Table 2).
Stable kidney function in LD was established at median of
5.5 days (range 5–8 days) while it was achieved at median of
17.5 days (range 6–30 days) in DD recipients. Among all
transplanted organs, one patient (graft from DD7) presented
delayed graft function and another (graft from LD4) never
attained a functional graft due to acute cellular rejection.
Also, a patient (graft from DD6) developed acute cellular re-
jection but attributable to lack of adherence to the
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immunosuppressive treatment. Additionally, two pa-
tients needed graft biopsies which revealed respect-
ively anti-calcineurinic toxicity and interstitial fibrosis
and tubular atrophy. Chronic humoral rejection was
absent in all patients. All the relevant information of
the graft outcome is detailed in Table 3.
One year after transplantation, 4 of 5 grafts from LD
and 11 of 12 grafts from DD were functional. One year
after KTx, serum creatinine levels were between 1.1–
1.2 mg/dL in the recipients of LD kidneys and 1.01–
2.6 mg/dL in the recipients of DD kidneys (normal range
0.7–1.3 mg/dL).
Isolation of uEVs from LDs and DDs
SEC-fractions were collected and analysed for tetraspanin
markers as a direct evidence of uEV presence. Figure 1
shows the typical SEC elution profile obtained, in which
uEVs eluted in fractions 7 to 9 according to the highest
fluorescence intensity for CD9 and CD63. uEV samples
from both LDs and DDs had the same distribution and no
changes were detected either for CD9 or CD63 MFI levels
(data not shown). From each sample, three chromato-
graphic fractions containing uEVs (those showing the
highest level of CD9 and CD63) were pooled in a final vol-
ume of 1.5 mL, and all the subsequent experiments were
performed using these pooled fractions.
Regardless of the type of donor, NTA analyses revealed
that uEVs had a size distribution modal range from 124 to
250 nm with a mean of 223 ± 30 nm. Particle concentra-
tion was well above 1010 particles/mL in all samples,
showing no differences between both groups. All together
these data indicated that uEVs from LDs and DDs did not
differ in terms of concentration, size distribution or pres-
ence of well-defined EV markers (data not shown).
Table 1 Clinical and Epidemiological characteristics of living and deceased donors









LD1 P,T 40–45 F – – – – 0.7 – – – – –
LD2 P,T 55–60 F – – – – 0.98 – – – – –
LD3 P,T 65–70 M – – – – 0.63 – – – – –
LD4 P,T 50–55 M – – Yes Hipotirodism 0.93 – – – simvastatin,
Levotiroxine
–
LD5 P,T 55–60 F – – – – 1.02 – – – – –




























DD6 P 45–50 M – – – Bone cyst 3.41 2 2 PTE oxcarbazepine, diazepam,
Celecoxib.
adrenaline
DD7 P 70–75 F – – Yes osteoporosis 0.73 3 2 Ictus Calcium noradrenaline
A summary of the age, gender, diseases, cause of death and medication of all the patients is included in this Table. P: sample used for proteomic assays. T:
sample used for NGS assays
F female, M male; HTA Hypertension, DM2 Diabetes Mellitus type 2, DLP Dyslipemia, CVA cerebrovascular accident, PTE Pulmonary thrombo-embolism, SrCr Serum
Creatinine, RK right kidney, LK left kidney
Table 2 Sample characterization
Living donor Deceased Donor
Urine samples n = 5 n = 7
Kidneys available for KTx n = 5 n = 14
Kidneys transplanted n = 5 n = 12
Functional organs (1 year after KTx) n = 4 n = 11
Sample size details from urine sample collection to recipients outcome
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RNA content of uEVs
The RNA content of uEVs was analysed in 5 LDs and 5
DDs. RNA species of < 200 nucleotides (nts) were de-
tected in all samples of both groups (Fig. 2). Of note, the
RNA profile analysis showed a high variability in the
amount of RNAs found in the different samples, inde-
pendently from the type of donors.
NGS results showed that miRNAs comprised around
the 30% of the total RNA content of uEVs, while the
remaining 70% was distributed among different RNA
species, including tRNA (20%), unmapped RNAs (15%),
and non-sense RNA (10%). Also, rRNAs and a minor
proportion of protein coding RNAs (< 10%) were found.
Given their relevance in cell regulation, miRNAs were
further analysed [47, 48].
A deeper analysis of miRNA content showed a high
correlation between samples regardless of the group (R
of Pearson 0.96 ± 0.02). The shared and unique miRNAs
found in LD and DD groups can be seen in the Venn
Diagram shown in Fig. 3a. Up to 205 miRNA sequences
were found to be present in all samples, from which a
5.4% (n = 10) have not been previously identified in EVs
according to specific databases [39, 42, 43] (Table 4).
These miRNAs were analysed with a target prediction
tool (mirdb.org/miRDB/) [45] and most of them are





















LD1 P, T 2 0 0 0 1 – P, B, FK, MMf – – – – 5 1
LD2 P, T 2 1 1 1 – – P, B, FK, MMf – – – – 6 1.2
LD3 P, T 2 1 1 2 – – P, B, FK, MMf – – – – 8 1.14
LD4 P, T 2 1 1 1 – – P, B, FK, MMf Yes Yes – ACR – –
LD5 P, T 4 1 2 1 – – P, B, FK, MMf
DD1 P, T 20 2 2 1 – – P, FK, MMf – – – – 14 1,82
Not transplanted
DD2 P,T 18 2 2 1 – – P, B, FK, MMf – – – – 20 1.77
22 0 0 1 – – P, B, FK, MMf – – – – 15 1.23
DD3 P,T 18 1 1 1 – – P, FK, Th, Everolimus – – – – 7 1.45
Not transplanted
DD4 T 20 1 1 1 – – P, B, FK, MMf – – – CNTI 15 1.67
15 1 2 1 – – P, B, FK, MMf – – – ATN, TAIF 6 2.6
DD5 T 20 1 2 2 – – P, B, FK, MMf – – – – 9 1.64
17 1 1 1 – – Eculizumab, P,
FK, MMF, Th
– – – – 24 1.39
DD6 P 13 2 2 1 – – P, B, FK, MMf – Yes – ACR 24 1.03
22 1 1 1 – Yes P,FK; MMf, Th – – – – 25 1.16
DD7 P 17 2 2 1 – – P, B, FK, MMf Yes – – – 30 1.01
20 1 1 1 – – P, B, FK, MMf – – – – 30 1.01
A summary of the HLA-mismatch, donor specific antibodies (DSA), cold ischemia time, previous transplants, immunosuppression treatment, delay graft function
and renal biopsy are provided. P: sample used for proteomic assays. T: sample used for transcriptomic NGS assays
KTx Kidney transplantation, DSA donor specific antibodies, IS immunosuppression treatment, ACR acute cellular rejection, CHR chronic humoral rejection, KB kidney
biopsy, P Prednisone, FK Tacrolimus, MMf mycophenolate mofetil, B Basiliximab, Th Thymoglobulin, ATN Acute tubular necrosis, CNIT calcineurin inhibitor toxicity,
TAIF tubular atrophy and interstitial fibrosis, AS arteriosclerosis
Fig. 1 Representative elution profile of uEVs by size-exclusion
chromatography (SEC). The expression of CD63 and CD9, depicted
as the median fluorescence intensity (MFI, left axis), indicates uEVs
presence in SEC fractions. Isotype control is depicted by a dotted
line. The total protein content (mg/ml; right axis) was measured in
each SEC fraction
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predicted to target genes related with the urinary tract
such as ion channels (SLCs) and aquaporins (AQ),
among others.
On the other hand, despite the good correlation found,
a higher number of miRNAs was found in LDs com-
pared to DDs (a total of 66 sequences, 24% of miRNAs
found in LDs). To further investigate the potential role
of the miRNAs exclusively detected in LDs (n = 66) and
DDs (n = 7), these miRNAS were analysed by target
prediction analysis. A total of 4225 potentially targeted
genes were identified for LD miRNAs (target score over
90%), while 367 potentially targeted genes were identi-
fied for DD miRNAs. GO analyses of these potential tar-
gets revealed that, in comparison to the DD group, the
LD group showed an overrepresentation of genes in-
volved in cell adhesion, vesicle mediated transport and
cytoskeleton organization, while genes related with regu-
lation of the metabolism were underrepresented.
To investigate whether these differences could segre-
gate different patterns of expression specifically related
to the type of donor (which could be of relevance for the
graft outcome), hierarchical clustering of miRNAs found
was performed (Fig. 3b). Interestingly, no aggregation
was detected, meaning that both types of samples
showed a similar profile. Moreover, volcano plot re-
vealed only one miRNA differentially overexpressed in
LD (miR-326; p < 0.05) (Fig. 3c). Despite the differences
found in the content of miRNAs, the analyses revealed
similar profiles between uEVs from LD and DD.
Proteomic content of uEVs
Analogously to RNA studies, the proteomic profile was
determined on uEVs from LDs and DDs (n = 5 each).
Fig. 2 Representative profile of Small RNA from uEVs isolated by size-
exclusion chromatography. Total RNA extracted from pooled uEVs
profiled by small RNA gel electrophoresis showed a main peak at 60
nucleotides (P3) and a minor peak of RNA around 10–40 nucleotides
(P2). The lower marker of the small RNA kit can be observed at 4
nucleotides (P1). A representative experiment is shown
Fig. 3 miRNA analysis of uEV from living and deceased donor. a Venn diagrams showing the shared and differential miRNA content in uEVs from
LD (n = 5) and DD (n = 5) detected by next generation sequencing. 205 miRNAs overlap amongst the different samples analysed of LD and DD.
Only the miRNAs shared within all donors of each group were taken for analysis. b Hierarchical clustering analysis of LD and DD uEV samples.
Differential analysis of the miRNA content of uEVs from LD and DD. c Scatter plot analysis of miRNAs found in uEVs from LD and DD. Dot plot
representing the -log of the p-value and the difference between the miRNA expression of LD and DD groups. Interestingly, only one miRNA was
identified as statistically over-represented in LD (in bold, p < 0.05)
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Unfortunately, two of the samples of the DD could not
be used for proteomic analysis due to rather low protein
content, and were replaced by two different samples
(not previously analysed for miRNA).
Only proteins identified by at least two unique pep-
tides were considered in the analysis and raw data was
cleaned up from known contaminants such as keratins
and Tamm-Horsfall protein. Under these conditions,
more than 500 proteins were identified in both groups.
Of note, intra-group Pearson correlation values were
lower in the DD group (R values 0.53 ± 0.22) compared
with the LD group (0.61 ± 0.12), indicating a higher het-
erogeneity amongst the DD samples. This was also
depicted by Venn diagrams showing up to 137 proteins
shared by all LDs (Fig. 4a) while only 59 proteins were
shared by all DDs (Fig. 4b). Most of the proteins shared
by all DDs (83%, 49 proteins) were also found in all LDs.
The majority of these coincident proteins have been
previously described as related to EVs, including
Ezrin (EZR), Galectin-3-binding protein (LGALS3BP)
and Annexins (ANXA). In addition, proteins related
to the urinary system such as Neprilysin (NEP),
Table 4 miRNAs found by size-exclusion chromatography not












miRNAs found by size-exclusion chromatography and shared between LDs
and DDs (n = 205) were compared with those reported in specific databases
(EVpedia, Exocarta and Vesiclepedia). Those miRNAs not previously reported in























Fig. 4 Protein analysis uEV from living and deceased donor by LC/MS-MS. Venn diagrams showing the overlap of proteins detected in uEVs from
LD (a) and DD (b). c Hierarchical clustering analysis according to the protein content of uEVs from LD and DD. The analysis did not segregate
samples in their corresponding group. d Scatter dot plot analysis of the protein content of uEVs from LD and DD. Scatter plot representing the
-log of the p-value and the differences between LD and DD group
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Aminopeptidase N (ANPEP), Aquaporin-1 (AQP1) and
several ion transporters are also be found in both groups.
When these results were further compared to investi-
gate whether a different uEVS proteomic profile could
not be detected between LD and DD, neither hierarch-
ical clustering nor differential expression analyses re-
vealed a pattern or proteins differentially expressed by
LDs and DDs (Fig. 4c and d, respectively). This lack of
clear segregation among samples indicates a similar
uEVs profile regardless the donor’s origin.
Discussion
In this pilot study, we aimed to characterise the miRNA
and protein profiles of SEC-isolated uEVs from living and
deceased kidney donors to profile the organ status before
Kidney transplantation (KTx). Several factors account for
the outcome of KTx, including those related to the charac-
teristics of the donor [2–4, 11]. Although one of the most
important factors directly affecting KTx outcome is the
time of cold ischemia, which is usually longer in DD or-
gans, an additional factor to be considered is the status of
the organ before the extraction. This could be affected by
several factors such as age, donor general condition, or
cause of death in DDs. In these aspects, the cohort of pa-
tients included in this pilot study shared the same charac-
teristics of larger reported cohorts in terms of mean age
and cold ischemia time in DD.
Acceptance of a given organ for transplantation is cur-
rently based on clinical and histopathological parameters.
The latter are based on a kidney biopsy prior to transplant-
ation, performed only under some circumstances -such as
donors aged > 60 years old, or suffering from cardiovascular
disorders-, with the aim to verify the quality of the kidney.
Yet, as biopsy sampling variability and differences in criteria
of analysis may lead to different assessment of the quality
of the organ [49, 50], gathering additional information
(such that found in uEVs) may be of help defining clearer
criteria for organ acceptance.
Given that organ transplant donor characteristics are
evolving to older donors (most of them with chronic
pathologies) pre-transplant biopsy in these expanded cri-
teria donors is highly recommended to evaluate the state
of the organ. As kidney biopsies have limitations, there
is a need to improve the analysis of the kidney status
prior to transplantation. In this context, the content of
uEVs that come from the excretory system may be of
interest. Several studies have already shown that urinary
EVs may contain specific signatures which may poten-
tially serve as biomarkers of disease [20]. Similarly, nor-
mal kidneys also produce EVs, and their specific profile
may be indicative of the physiological status of each par-
ticular organ. Profiling some specific markers found in
urinary EVs may be of clear interest in this particular
scenario as a source of non-invasive diagnostic and
prognostic biomarkers on the kidney status before
nephrectomy.
Most of uEV-related parameters, such as size, concen-
tration and the presence of classical EV markers -includ-
ing tetraspanins CD63 and CD9- were equally detected
in LD and DD samples. Moreover we did not detect in
our DD-uEVs preparations any contamination of apop-
totic bodies-such as the presence of histones-, which
could be expected after the inflammatory state produce
by brain death [13, 51]. In this sense, the absence of
plasma EVs markers (such as CD5L or moesin), supports
that urinary derived EVs are mainly analysed.
Focusing on the study of the RNA content of
SEC-isolated uEVs, and in line with previous studies
based on ultracentrifuged samples [52], miRNAs and, to
a lesser extent, tRNA and rRNA, were among the most
abundant RNA species in uEVs. Given the prominent
role of miRNAs in cell communication and regulation,
we focused on their profile in LD and DD. Although
most miRNAs found in DDs were also present in LDs,
up to 24% of miRNAs (mainly related to cell communi-
cation and signal transduction) were detected only in
LDs. The miRNA target prediction showed that those
genes related with cell adhesion, vesicle mediated trans-
port and cytoskeleton organization were overrepresented
in LD compared to DD, while genes related to regulation
of metabolism were underrepresented. These data may
be suggestive of an alteration in intracellular trafficking
and metabolism in DD. Yet, due to the complexity of
miRNA regulation processes and the multiples targets
described for a given specific miRNA, further studies are
needed to reveal the functional implication of each of
them in the specific nephrologic context.
In fact, only one miRNA (miR-326) was found to be
over-represented in LD group. miR-326 was described
previously in EVs derived from cancer cell lines [53],
plasma [54] and endothelial cells [55], and it has been
described to target bcl–xL, a member of the bcl-2 family,
inducing apoptosis in human platelets [56]. It has also
been reported that down-regulation of miR-326 may be
involved in chemoresistance in lung cancer [57], poor
prognosis and metastatic gastric cancer [58, 59] and
osteosarcoma [60]. But the presence of this miRNA was
not found before in uEVs and its role in the urinary
track remains unknown.
Additionally, we further detected eleven miRNAs not
described previously in EVs databases which are pre-
dicted to target genes related with the urinary tract.
Once again, SEC is confirmed as confident method for
isolating uEVs isolated and can be used for EV-related
RNA studies and points out to their relevance in normal
kidney function.
Focusing on the proteomic studies, and as seen in the
miRNA data, a first observation was the identification of
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higher number of proteins in LDs compared to DDs. In
addition, intra-group analyses demonstrated a higher
level of variability of protein expression among DDs,
which could be related to intrinsic or extrinsic factors
such as the donor-conditioning regime. Despite the min-
imal differences detected between LD and DD in the
proteomic and miRNA analysis, in this study all trans-
planted organs were functional 1 year after KTx, indicat-
ing that these minimal changes seem not to be of major
relevance for organ function.
Currently, the majority of transplanted kidneys are ob-
tained from aged DDs in a state of neurological death.
The use of drugs and medical intervention to maintain
these donors in optimal conditions may alter the organ,
as suggested by Nemati et al. [61]. Our results show that,
before nephrectomy, uEVs derived from DDs showing a
1 year follow-up normal functioning kidneys, contained
minimal alterations in their miRNA composition com-
pared to uEVs from LDs. On the other hand, although
the DD protein content was highly heterogeneous; such
differences did not correlate with the short-term (1 year)
graft survival. Additional studies, in a larger cohort of
donors and recipients, are needed to investigate whether
the information contained in uEVs from subclinical al-
tered kidneys could anticipate any detrimental effect on
the graft after transplantation, as recently suggested
using preservation fluids [26]. Despite there are some
limitations in our pilot study, such as a reduced number
of samples and a high variability found among donors,
we have successfully profiled uEVs from kidney donors.
These results although preliminary, open the possibility
to analyse donor uEVs in search of potential biomarkers
of kidney quality before nephrectomy.
Conclusions
Based on uEVs miRNA and proteomic data, no major dif-
ferences could be detected between LDs and DDs, suggest-
ing that the physiological status of the well-functioning
organs before nephrectomy was similar in both groups.
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